ESMO 2024: Dr. Jonasch on implications of positive HIF-2α inhibitor data in ccRCC
Eric Jonasch, MD, discusses the potential implications and next steps for the investigational HIF-2α inhibitor NKT2152, which showed strong anti-tumor activity in advanced clear cell renal cell carcinoma patients, based on findings from a phase 1/2 study presented at the 2024 ESMO Congress. Jonasch highlights the need for a registrational strategy and further research on patient response and combination therapies.
Related Clinical Trials
Reference News
Eric Jonasch, MD, discusses the potential implications and next steps for the investigational HIF-2α inhibitor NKT2152, which showed strong anti-tumor activity in advanced clear cell renal cell carcinoma patients, based on findings from a phase 1/2 study presented at the 2024 ESMO Congress. Jonasch highlights the need for a registrational strategy and further research on patient response and combination therapies.